HCA (HCA) Cowen Maintains Buy, PT Raised to $561 March 2026

Cowen & Co. maintained a Buy on HCA Healthcare, Inc. (HCA) and raised its price target to $561 on March 10, 2026. The HCA analyst rating was recorded at 09:09 AM ET and shows a modest near-term market reaction, with the stock moving 0.23% ($1.25) on the update. This notice summarizes the rating action, the new HCA price target, the market context, and what investors should watch next.

HCA analyst rating: Cowen Maintains Buy and Raises PT to $561

On March 10, 2026 at 09:09 AM, Cowen & Co. maintained its Buy rating on HCA Healthcare, Inc. (HCA) and raised the price target to $561. The update was reported by StreetInsider and lists a 0.23% ($1.25) price change since the note, reflecting limited intraday reaction. StreetInsider

HCA analyst rating: What Cowen’s Maintained Buy Means for Investors

A maintained Buy with a higher PT signals Cowen’s continued confidence in HCA’s underlying earnings mix and cash flow. For investors, this means the firm expects HCA’s fundamentals to support further upside to the new $561 target, rather than an immediate tactical trade call.

HCA analyst rating: Stock performance and market context

HCA Healthcare, Inc. (HCA) carries a market cap of $120,255,074,272. The small 0.23% ($1.25) move after Cowen’s note suggests the market had largely priced in Cowen’s view or saw the change as incremental. Investors should watch earnings, same-hospital revenue, and margins for signs the PT is achievable.

HCA analyst rating: Historical analyst coverage snapshot

HCA has long been covered by major brokerages, with recurring Buy and Hold recommendations tied to hospital utilization and reimbursement outlook. Cowen’s maintained Buy fits that pattern of constructive coverage, while price targets have trended with hospital throughput and margin expectations.

HCA analyst rating: Key implications and next steps for investors

Investors should treat this Cowen note as confirmation of a positive view, not a fresh upgrade. Key near-term catalysts include quarterly results, policy shifts on reimbursements, and labor cost trends. Use the $561 PT as a directional guide and monitor reported revenue and margins against consensus.

HCA analyst rating: Meyka AI grade and model view

Meyka AI rates HCA with a grade of A. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI’s models add context to the Cowen view but do not replace investor due diligence.

Final Thoughts

Cowen & Co.’s March 10, 2026 note kept a Buy on HCA Healthcare, Inc. (HCA) while raising the price target to $561, a signal of continued analyst confidence without an outright upgrade. The limited 0.23% ($1.25) stock move suggests investors saw this as an incremental, not transformational, change. For portfolio managers and individual investors, the update affirms HCA’s earnings resilience and cash flow outlook, but it is not a substitute for fresh fundamental evidence. Maintain position sizing discipline and watch upcoming quarterly results, reimbursement policy updates, and margin trends as the most relevant tests of the new target. Remember that Meyka AI rates HCA with a grade of A. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. These grades are not guarantees and are not financial advice. Use them alongside your own analysis and risk tolerance.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Analyst ratings are opinions and not guarantees of future performance. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.